Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma

<p>Validation cohort, patient flow diagram. Patient enrollment and final inclusion of FFPE tissue samples in this study is shown. n = 3 patients were excluded from enrollment for reasons listed. The validation cohort comprised paired tissue samples from a total of n = 38 patients. Detailed cha...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Sied Kebir (15048732) (author)
Rannpháirtithe:	Vivien Ullrich (15048735) (author), Pia Berger (15048738) (author), Celia Dobersalske (15048741) (author), Sarah Langer (15048744) (author), Laurèl Rauschenbach (15048747) (author), Daniel Trageser (15048750) (author), Andreas Till (15048753) (author), Franziska K. Lorbeer (15048756) (author), Anja Wieland (15048759) (author), Timo Wilhelm-Buchstab (15048762) (author), Ashar Ahmad (15048765) (author), Holger Fröhlich (8724576) (author), Igor Cima (15048768) (author), Shruthi Prasad (15048771) (author), Johann Matschke (15048774) (author), Verena Jendrossek (15048777) (author), Marc Remke (14962619) (author), Barbara M. Grüner (14947089) (author), Alexander Roesch (15048780) (author), Jens T. Siveke (11780911) (author), Christel Herold-Mende (15047946) (author), Tobias Blau (15048783) (author), Kathy Keyvani (15048786) (author), Frank K.H. van Landeghem (15048789) (author), Torsten Pietsch (15048792) (author), Jörg Felsberg (15048795) (author), Guido Reifenberger (12335398) (author), Michael Weller (15037908) (author), Ulrich Sure (15048798) (author), Oliver Brüstle (15048801) (author), Matthias Simon (15048804) (author), Martin Glas (15048807) (author), Björn Scheffler (15048810) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Therapeutic Research and Development Clinical Research and Trials CNS Cancers Gliomas, Glioblastomas Drug Targets Precision Medicine
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
de réir: Sied Kebir (15048732)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
de réir: Sied Kebir (15048732)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
de réir: Sied Kebir (15048732)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
de réir: Sied Kebir (15048732)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
de réir: Qingsheng Xu (17078830)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
de réir: Qingsheng Xu (17078830)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S7 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
de réir: Tobias Kessler (17079209)
Foilsithe / Cruthaithe: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
de réir: Bachchu Lal (17141949)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
de réir: Francesca Orzan (15055579)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
de réir: Francesca Orzan (15055579)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
de réir: Francesca Orzan (15055579)
Foilsithe / Cruthaithe: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
de réir: Defne Bayik (14961098)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
de réir: Isha Mondal (16721699)
Foilsithe / Cruthaithe: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
de réir: William Kelly (15439117)
Foilsithe / Cruthaithe: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
de réir: William Kelly (15439117)
Foilsithe / Cruthaithe: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
de réir: Michael Kilian (16697663)
Foilsithe / Cruthaithe: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
de réir: Michael Kilian (16697663)
Foilsithe / Cruthaithe: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
de réir: Michael Kilian (16697663)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
de réir: Anne-Florence Blandin (15056366)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
de réir: Mengjie Zhao (14845174)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
de réir: Mengjie Zhao (14845174)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
de réir: Mengjie Zhao (14845174)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
de réir: Mengjie Zhao (14845174)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
de réir: Mengjie Zhao (14845174)
Foilsithe / Cruthaithe: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
de réir: Joseph Toker (15399882)
Foilsithe / Cruthaithe: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
de réir: Joseph Toker (15399882)
Foilsithe / Cruthaithe: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
de réir: Joseph Toker (15399882)
Foilsithe / Cruthaithe: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
de réir: Joseph Toker (15399882)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_h6pabi0n735jbsffs6qa0v2gmq